John M. L. Ebos

Publications

• Preclinical Recapitulation of Antiangiogenic Drug Clinical Efficacies Using Models of Early or Late Stage Breast Cancer Metastatis
  Breast (Edinburgh, Scotland). Aug, 2013  |   Pubmed ID: 24074794
• Mind the Gap: Potential for Rebounds During Antiangiogenic Treatment Breaks
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2012  |   Pubmed ID: 22679177
• Antiangiogenic Therapy: Impact on Invasion, Disease Progression, and Metastasis
  Nature Reviews. Clinical Oncology. Apr, 2011  |   Pubmed ID: 21364524
• Peering into the Aftermath: The Inhospitable Host?
  Nature Medicine. Oct, 2010  |   Pubmed ID: 20930748
• Tumor and Host-mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Aug, 2009  |   Pubmed ID: 19671869
• Dose-dependent Increases in Circulating TGF-alpha and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2009  |   Pubmed ID: 19276250
• Accelerated Metastasis After Short-term Treatment with a Potent Inhibitor of Tumor Angiogenesis
  Cancer Cell. Mar, 2009  |   Pubmed ID: 19249681
• Vascular Endothelial Growth Factor-mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels As a Surrogate Biomarker for Tumor Growth
  Cancer Research. Jan, 2008  |   Pubmed ID: 18199548
• Multiple Circulating Proangiogenic Factors Induced by Sunitinib Malate Are Tumor-independent and Correlate with Antitumor Efficacy
  Proceedings of the National Academy of Sciences of the United States of America. Oct, 2007  |   Pubmed ID: 17942672
• Cellular and Molecular Surrogate Markers to Monitor Targeted and Non-targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose
  Current Cancer Drug Targets. Nov, 2005  |   Pubmed ID: 16305351
• Down-regulation of DNA Mismatch Repair Proteins in Human and Murine Tumor Spheroids: Implications for Multicellular Resistance to Alkylating Agents
  Molecular Cancer Therapeutics. Oct, 2005  |   Pubmed ID: 16227397
• Increased Plasma Vascular Endothelial Growth Factor (VEGF) As a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies
  Cancer Research. Sep, 2004  |   Pubmed ID: 15374976
• A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma
  Molecular Cancer Research : MCR. Jun, 2004  |   Pubmed ID: 15235107
• Dok-R Binds C-Abl and Regulates Abl Kinase Activity and Mediates Cytoskeletal Reorganization
  The Journal of Biological Chemistry. Aug, 2003  |   Pubmed ID: 12777393
• Imatinib Mesylate (STI-571) Reduces Bcr-Abl-mediated Vascular Endothelial Growth Factor Secretion in Chronic Myelogenous Leukemia
  Molecular Cancer Research : MCR. Dec, 2002  |   Pubmed ID: 12496355